BioDiem welcomes inquiries from potential partners on the licensing opportunities available. BioDiem has world-class in-house expertise in the areas of vaccines and infectious disease therapy development. The Company also has an existing partnering network that spans the globe, which has provided access to top research facilities in the development of its asset portfolio.
Non-confidential summaries of each licensing opportunity are available upon request from the Company. Contact info@biodiem.com
The following technologies are available for licence as detailed below:
| Product/technology | Indication | Licenses Available |
| LAIV mammalian cell based | Influenza | Europe US Japan Other countries except Russia and CIS. |
| LAIV egg based | Influenza | Europe (excluding Russia & CIS) Japan USA |
| LAIV viral vector | Vaccine Vector | Co-development licences (GMP LAIV material available) |
| Flavivirus vector technology | Flavivirus (dengue, murray river, encephalitis, Japanese encephalitis, etc) | Worldwide rights for co-development or out-licence |
| BDM-E | Retinitis Pigmentosa | Worldwide rights for co-development or out-licence (except Russia & CIS) |
| BDM-I | Antimicrobial | Worldwide rights for co-development |